Advances in research on immune checkpoint and its inhibitors in glioma / 中国药科大学学报

ABSTRACT

@#Conventional treatment of glioma has not significantly improved the prognosis of patients, so people pay more attention to the potential of immuno-checkpoint inhibitors in the treatment of glioma. This article reviews the expression and mechanism of some negative immune checkpoints in gliomas, such as programmed death-1 (PD-1), programmed death ligand-1 (PD-L1), cytotoxic T lymphocyte antigen-4 (CTLA-4), T-cell immunoglobulin and mucin-domain containing-3 (TIM-3), lymphocyte-activation gene-3 (LAG-3), T cellimmunoreceptor with Ig and ITIM domains (TIGIT), B7-H4 and V-domain immunoglobulin suppressor of T-cell activation (VISTA), as well as progress of immune checkpoint inhibitors in clinical research, with a prospect of their future in immunotherapy.